Solid & Liquid Dose Drug Manufacturing & Development

Solid & Liquid Dose Drug Manufacturing & Development
Product Description

From OTC and Rx to diagnostics and dietary supplements, Avéma manufactures a full range of solid and liquid dose products, all manufactured under strict FDA guidelines and cGMP compliance. With an ever-growing portfolio of innovative formulas and a diverse mix of state-of-the-art equipment, our offerings add diversity, quality and value to your product line. Avéma is a strong partner in the development process, providing sound scientific and technical expertise, excellent project management skills and exceptional communications. Our extensive library of formulations provides a crucial building block for many products and our specific manufacturing expertise helps shorten development time and reduce costs.

Read more Show less

Avema Pharma Solutions

  • US
  • 2017
    On CPHI since
  • 1
    Certificates
Company types
Contract Service
View company profile
Categories
more categories Show less

Avema Pharma Solutions

  • US
  • 2017
    On CPHI since
  • 1
    Certificates
Company types
Contract Service
View company profile

More Products from Avema Pharma Solutions (4)

  • Research & Development

    Product Research & Development

    Avéma offers formulation, process and analytical development support of new or existing products using the most current and effective active ingredients and delivery systems. Our team of scientists bring decades of pre-formulation development expertise to your products, combined with the knowledge of how t...
  • ANDA and NDA Technical Support

    Product ANDA and NDA Technical Support

    As part of its commitment to full service support, Avéma Contract Services is pleased to offer our customers support with ANDA and NDA applications, including bio equivalency studies, collecting background data, supervising technology tranfers and reviewing applications to make sure that companies com...
  • Commercial Manufacturing

    Product Commercial Manufacturing

    Covering a 135,000ft² area, our Miami facility is registered with the FDA and complies fully with current good manufacturing practice (cGMP) guidelines. It has the capacity for R&D, process development and small-scale launches, including pilot-scale cGMP manufacturing and packaging to support pilot pharmac...
  • Formulation Development

    Product Formulation Development

    Avéma has an extensive library of formulations and more than 40 years of Rx formulation development experience.

Avema Pharma Solutions resources (2)

  • Lessons Learned: Choosing & Managing a CDMO

    Brochure Lessons Learned: Choosing & Managing a CDMO

    Lessons Learned: Choosing & Managing a CDMOAvéma Pharma Solutions, a division of PL Developments (PLD), is in the unique position being both a consumer and supplier of global CDMO services for both OTC and rX products. In this presentation, we’ll explore the lessons we have learned from managing our own CMOs that have allowed us to build a better CDMO model for our Avéma customers. We’ll address the areas that can help speed up your time-to-market, keep development costs under control, and smooth the FDA approval and commercial launch process. Watch our webinar at https://app.webinar.net/K2OlZE6JLx9?mcc=WebsitePost
  • The Promise of Gummies as a Drug Delivery System

    Video The Promise of Gummies as a Drug Delivery System

    The global gummy vitamin market is expected to reach 10.6 billion by 2025 and gummies are gaining traction as a drug delivery system -- especially for children and seniors who resist taking pills, capsules and liquids. Mitchell Slade, who brings more than 20 years of gummy manufacturing experience at Nature’s Bounty to the table, will address the challenges of developing gummies beyond supplements, such ensuring consistent dosage, production and taste. Avéma/PLD has a world-class GDUFA facility that is CFR 211 and CFR 111 certified, uses a starchless gummy manufacturing process and brings 40+ years of formulating experience to the development of innovative drug delivery systems.
    2024-05-17